Phosphorylation of estrogen receptor α at serine 118 is correlated with breast cancer resistance to tamoxifen

Oncology Letters

Volumn 6, Issue 1, 2013, Pages 118-124

  Chen, Ming ^a,b   Cui, Yu Kun ^a   Huang, Wen He ^a   Man, Kwan ^c   Zhang, Guo Jun ^a,d  

^a CANCER HOSPITAL OF SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^b PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

^d SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

Breast cancer; Endocrine resistance; Estrogen receptor ; Phosphorylation; Tamoxifen

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; PROGESTERONE RECEPTOR; SERINE; SERINE 118; SERINE 167; TAMOXIFEN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; LYMPHOMA; MAJOR CLINICAL STUDY; MENOPAUSE; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SCORING SYSTEM; TUMOR VOLUME;

EID: 84878272950     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1324     Document Type: Article

References (22)

1. Lim E, Metzger-Filho O and Winer EP: The natural history of hormone receptor-positive breast cancer. Oncology (Williston Park) 26: 688-694, 696, 2012.
2. Murphy LC, Seekallu SV and Watson PH: Clinical significance of estrogen receptor phosphorylation. Endocr Relat Cancer 18: R1-R14, 2011.
3. Becker MA, Ibrahim YH, Cui X, Lee AV and Yee D: The IGF pathway regulates ERα through a S6K1-dependent mechanism in breast cancer cells. Mol Endocrinol 25: 516-528, 2011.
4. de Leeuw R, Neefjes J and Michalides R: A role for estrogen receptor phosphorylation in the resistance to tamoxifen. Int J Breast Cancer 2011: 232435, 2011.
5. Green KA and Carroll JS: Oestrogen-receptor-mediated transcription and the influence of co-factors and chromatin state. Nat Rev Cancer 7: 713-722, 2007.
6. McCarty KS Jr, Miller LS, Cox EB, Konrath J and McCarty KS Sr: Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 109: 716-721, 1985.
7. Riggins RB, Schrecengost RS, Guerrero MS and Bouton AH: Pathways to tamoxifen resistance. Cancer Lett 256: 1-24, 2007.
8. Thibault C, Khodari W, Lequoy M, Gligorov J and Belkacémi Y: HER2 status for prognosis and prediction of treatment efficacy in adenocarcinomas: A review. Crit Rev Oncol Hematol 13: Apr 5, 2013 (Epub ahead of print).
9. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987.
10. Cittelly DM, Das PM, Salvo VA, Fonseca JP, Burow ME and Jones FE: Oncogenic HER2Δ16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors. Carcinogenesis 31: 2049-2057, 2010.
11. Yamashita H, Nishio M, Toyama T, et al: Low phosphorylation of estrogen receptor alpha (ERalpha) serine 118 and high phosphorylation of ERalpha serine 167 improve survival in ER-positive breast cancer. Endocr Relat Cancer 15: 755-763, 2008.
12. Métivier R, Gay FA, Hübner MR, et al: Formation of an hER alpha-COUP-TFI complex enhances hER alpha AF-1 through Ser118 phosphorylation by MAPK. EMBO J 21: 3443-3453, 2002.
13. Zhu C, Qi X, Chen Y, Sun B, Dai Y and Gu Y: PI3K/Akt and MAPK/ERK1/2 signaling pathways are involved in IGF-1 induced VEGF-C upregulation in breast cancer. J Cancer Res Clin Oncol 137: 1587-1594, 2011.
14. Tai W, Qin B and Cheng K: Inhibition of breast cancer cell growth and invasiveness by dual silencing of HER-2 and VEGF. Mol Pharm 7: 543-556, 2010.
15. Mintz PJ, Habib NA, Jones LJ, et al: The phosphorylated membrane estrogen receptor and cytoplasmic signaling and apoptosis proteins in human breast cancer. Cancer 113: 1489-1495, 2008.
16. Guo JP, Shu SK, Esposito NN, Coppola D, Koomen JM and Cheng JQ: IKKepsilon phosphorylation of estrogen receptor alpha Ser-167 and contribution to tamoxifen resistance in breast cancer. J Biol Chem 285: 3676-3684, 2010.
17. Motomura K, Ishitobi M, Komoike Y, et al: Expression of estrogen receptor beta and phosphorylation of estrogen receptor alpha serine 167 correlate with progression-free survival in patients with metastatic breast cancer treated with aromatase inhibitors. Oncology 79: 55-61, 2010.
18. Murphy LC, Skliris GP, Rowan BG, et al: The relevance of phosphorylated forms of estrogen receptor in human breast cancer in vivo. J Steroid Biochem Mol Biol 114: 90-95, 2009.
19. Sarwar N, Kim JS, Jiang J, et al: Phosphorylation of ERalpha at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ERalpha phosphorylation in breast cancer progression. Endocr Relat Cancer 13: 851-861, 2006.
20. Murphy LC, Niu Y, Snell L and Watson P: Phospho-serine-118 estrogen receptor-alpha expression is associated with better disease outcome in women treated with tamoxifen. Clin Cancer Res 10: 5902-5906, 2004.
21. Murphy LC, Weitsman GE, Skliris GP, et al: Potential role of estrogen receptor alpha (ERalpha) phosphorylated at Serine118 in human breast cancer in vivo. J Steroid Biochem Mol Biol 102: 139-146, 2006.
22. Bhardwaj N, Carson MB, Abyzov A, Yan KK, Lu H and Gerstein MB. Analysis of combinatorial regulation: scaling of partnerships between regulators with the number of governed targets. PLoS Comput Biol 6: e1000755, 2010.